rosuvastatin
Selected indexed studies
- Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. (Am J Cardiovasc Drugs, 2020) [PMID:32648167]
- Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. (J Am Soc Nephrol, 2022) [PMID:35853713]
- Rosuvastatin: Beyond the cholesterol-lowering effect. (Pharmacol Res, 2016) [PMID:26930419]
_Worker-drafted node — pending editorial review._
Connections
rosuvastatin is a side effect of
Sources
- Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. (2020) pubmed
- Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. (2022) pubmed
- Rosuvastatin: Beyond the cholesterol-lowering effect. (2016) pubmed
- Rosuvastatin calcium: A comprehensive profile. (2026) pubmed
- Rosuvastatin--'the super statin'. (2001) pubmed
- Comparison of rosuvastatin 10 mg plus ezetimibe versus rosuvastatin 20 mg in atherosclerotic cardiovascular disease and type 2 diabetes. (2025) pubmed
- The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review. (2025) pubmed
- Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction? (2023) pubmed
- Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis. (2025) pubmed
- Rosuvastatin pharmacogenetics in African populations. (2018) pubmed